ANI Pharmaceuticals Inc (ANIP) stock
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$69.99−0.90 (-1.27%)
Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –
ANI Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
ANI Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $49.91M, down 7.4% year over year. For fiscal 2025 it was $51.66M, up 15.9% from the year before. Over ten years it grew 33.5% a year on average. The highest annual figure on record is $51.66M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.66M | +15.9% |
| FY2024 | Dec 31, 2024 | $44.58M | +30.0% |
| FY2023 | Dec 31, 2023 | $34.29M | +53.6% |
| FY2022 | Dec 31, 2022 | $22.32M | +96.3% |
| FY2021 | Dec 31, 2021 | $11.37M | -28.9% |
| FY2020 | Dec 31, 2020 | $16.00M | -19.2% |
| FY2019 | Dec 31, 2019 | $19.81M | +28.7% |
| FY2018 | Dec 31, 2018 | $15.39M | +69.7% |
| FY2017 | Dec 31, 2017 | $9.07M | +212.1% |
| FY2016 | Dec 31, 2016 | $2.91M | +1.1% |
| FY2015 | Dec 31, 2015 | $2.87M | +7.3% |
| FY2014 | Dec 31, 2014 | $2.68M | +56.4% |
| FY2013 | Dec 31, 2013 | $1.71M | +47.8% |
| FY2012 | Dec 31, 2012 | $1.16M | -97.4% |
| FY2011 | Dec 31, 2011 | $44.18M | +11.3% |
| FY2010 | Dec 31, 2010 | $39.71M | +190.2% |
| FY2009 | Dec 31, 2009 | $13.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.75M | -10.8% |
| Q1 FY2026 | Mar 31, 2026 | $10.60M | +0.3% |
| Q4 FY2025 | Dec 31, 2025 | $12.26M | -26.3% |
| Q3 FY2025 | Sep 30, 2025 | $12.30M | +21.5% |
| Q2 FY2025 | Jun 30, 2025 | $16.54M | +126.6% |
| Q1 FY2025 | Mar 31, 2025 | $10.56M | +0.5% |
| Q4 FY2024 | Dec 31, 2024 | $16.65M | +68.7% |
| Q3 FY2024 | Sep 30, 2024 | $10.13M | -8.9% |
| Q2 FY2024 | Jun 30, 2024 | $7.30M | -1.1% |
| Q1 FY2024 | Mar 31, 2024 | $10.51M | +77.4% |
| Q4 FY2023 | Dec 31, 2023 | $9.87M | +89.0% |
| Q3 FY2023 | Sep 30, 2023 | $11.12M | +45.2% |
| Q2 FY2023 | Jun 30, 2023 | $7.37M | +77.0% |
| Q1 FY2023 | Mar 31, 2023 | $5.92M | +12.3% |
| Q4 FY2022 | Dec 31, 2022 | $5.22M | +66.3% |
| Q3 FY2022 | Sep 30, 2022 | $7.66M | +211.8% |
| Q2 FY2022 | Jun 30, 2022 | $4.17M | +48.5% |
| Q1 FY2022 | Mar 31, 2022 | $5.27M | +77.7% |
| Q4 FY2021 | Dec 31, 2021 | $3.14M | -14.7% |
| Q3 FY2021 | Sep 30, 2021 | $2.46M | -16.4% |
| Q2 FY2021 | Jun 30, 2021 | $2.81M | -7.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.97M | -53.2% |
| Q4 FY2020 | Dec 31, 2020 | $3.68M | -21.3% |
| Q3 FY2020 | Sep 30, 2020 | $2.94M | -41.0% |
| Q2 FY2020 | Jun 30, 2020 | $3.04M | -47.4% |
| Q1 FY2020 | Mar 31, 2020 | $6.34M | +45.1% |
| Q4 FY2019 | Dec 31, 2019 | $4.68M | +34.3% |
| Q3 FY2019 | Sep 30, 2019 | $4.98M | +6.7% |
| Q2 FY2019 | Jun 30, 2019 | $5.77M | +12.4% |
| Q1 FY2019 | Mar 31, 2019 | $4.37M | +108.0% |
| Q4 FY2018 | Dec 31, 2018 | $3.48M | +31.3% |
| Q3 FY2018 | Sep 30, 2018 | $4.67M | +77.2% |
| Q2 FY2018 | Jun 30, 2018 | $5.14M | +137.1% |
| Q1 FY2018 | Mar 31, 2018 | $2.10M | +29.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.65M | +1863.7% |
| Q3 FY2017 | Sep 30, 2017 | $2.63M | +153.0% |
| Q2 FY2017 | Jun 30, 2017 | $2.17M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.62M | – |
| Q4 FY2016 | Dec 31, 2016 | $135.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $1.04M | – |
See a number that looks wrong?